dopetalk
Core Topics => Drugs => Other => Topic started by: Chip on May 22, 2018, 04:52:45 AM
-
source: https://www.neuralstem.com/pipeline/ns-566
(I have frequent back pain from an old IV injury (L2) so I am wondering if this may help ...)
About Chronic Spinal Cord Injury (cSCI)
A spinal cord injury, or SCI, generally refers to any injury to the spinal cord that is caused by trauma instead of disease although in some cases, it can be the result of diseases.
It is estimated that there are 12,500 new cases of SCI per year and that at any given time, there are between 240,000 and 337,000 people in the United States that are living with SCI.
Chronic spinal cord injury (cSCI) generally refers to the phase beginning 6 months after the initial injury. SCIs are most often traumatic, caused by lateral bending, dislocation, rotation, axial loading, and hyperflexion or hyperextension of the cord or cauda equina.
Motor vehicle accidents are the most common cause of SCIs, while other causes include falls, work-related accidents, sports injuries, and penetrations such as stab or gunshot wounds.
In certain instances, SCIs can also be of a non-traumatic origin, as in the case of cancer, infection, intervertebral disc disease, vertebral injury and spinal cord vascular disease.
NSI-566 as a Potential Treatment
We believe that NSI-566 may provide an effective treatment for cSCI by "bridging the gap" in the spinal cord circuitry created in traumatic SCI and providing new cells to help transmit the signal from the brain to points at or below the point of injury. We are carrying out a Phase 1 trial to test the safety and feasibility of this possibility.
The study has enrolled four AIS-A thoracic spinal cord injury subjects (motor and sensory complete), one to two years post-injury at the time of stem cell treatment. The stem cell treatment was found to be safe and well-tolerated by the subjects enrolled and there were no serious adverse events at six-months post transplantation. Subjects are currently being monitored for long-term follow-up evaluations. The FDA has approved the protocol amendment to treat an additional cohort of four cervical SCI patients. Substantially all the clinical costs of this study have been, and will continue to be, funded by grants arranged through the University of California, San Diego.
take the source link for more applications